**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Sankar Chatterjee, et al. Confirmation

Confirmation No.: Not Yet Assigned

**Application No.: 10/685,923** 

Group Art Unit: Not Yet Assigned

Filing Date: October 14, 2003

**Examiner: Not Yet Assigned** 

For: PEPTIDE-CONTAINING ALPHA-KETOAMIDE CYSTEINE AND SERINE

PROTEASE INHIBITORS

DATE OF DEPOSIT

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,

VA 22313-1430.

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

	the above identified	application as set forth in § 1.491, before the mailing date
	of a first Office Act	ion on the merits of the above-identified application, or
·	before the mailing d	ate of a first Office Action after the filing of request for
	continued examination	on under § 1.114, no additional fee is required.
	In accordance with §	1.129(a), this Information Disclosure Statement is being
	filed in connection	with  the first or  second After Final Submission,
	therefore:	
	☐ Certif	ication in Accordance with § 1.97(e) is attached; or
	The fe	ee of \$180.00 as set forth in § 1.17(p) is attached.
	In accordance with	§ 1.97(c), this Information Disclosure Statement is being
	filed after the period	set forth in § 1.97(b) above but before the mailing date of
	either a Final Action	under § 1.113 or a Notice of Allowance under § 1.311, or
	before an action that	otherwise closes prosecution in the application, therefore:
		Certification in Accordance with § 1.97(e) is attached;
		or
		The fee of \$\frac{\\$180.00}{}\$ as set forth in \\$ 1.17(p) is attached.
	In accordance with	§ 1.97(d), this Information Disclosure Statement is being
	filed after the mailin	g date of either a Final Action under § 1.113 or a Notice
	of Allowance under	§ 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, the	erefore included are: Certification in Accordance with §
	1.97(e); and the subn	nission fee of \$180.00 as set forth in § 1.17(p).
	Copies of each of the	ne references listed on the attached Form PTO-1449 are
	enclosed herewith	

- Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

## **EXCEPT THAT:**

- In view of the voluminous nature of references 4 and 10, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§ 120 have been made in the instant application:
  - Copies of references 1-11, 16-32 and 39 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/166,808 now U.S. Patent No. 6,150,378, filed October 6, 1998; copies of references 12-15 and 33 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/527,540 now U.S. Patent 6,288,231, filed March 16, 2002; copies of references 34-36 and 40 listed on the attached Form

## DOCKET NO.: CEPH-2313/CP188-C - 4 -

PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/879,336, filed June 12, 2001.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Date: November 19, 2003

Registration No. 36,697

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2003 WW





Chemical Abstract, <b>1994</b> , <i>Vol. 120(13)</i> , page 1236, Abstract No. 164625 <b>9</b> Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, <b>1992</b> , <i>Vol. 116(25)</i> , page 838, Abstract No. 256040	Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce			Docket No CEPH-23	o. 13/CP188-C	Application No. 10/685,923		
Patent and Trademark Office  October 14, 2003  Not Yet Assigned  Oothober 14, 2003  Not Yet Assigned  Oothober 14, 2003  Oothober 14, 2003  Not Yet Assigned  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  1 Amparo, E. C. et al., "Preparation of .alphaaminoboronic acid and ester as inhibitors of thrombin", Chemical Abstract, 1996, Vol. 125(17), page 1172, Abstract No. 222432  2 Amparo, E.C. et al., "Boronic acid and ester inhibitors of thrombin", Chemical Abstract, 1997, Vol. 126(3), page 594, Abstract No. 31466  3 Bihovsky et al., "Preparation of benzothiazine- and related heterocyclic group-containing amino acids as cysteine and serine protease inhibitors", Chemical Abstract, 1998, Vol. 129, WO 98/21186, Abstract No. 28214  * 4 Green, T.W., et al., Protective Groups in Organic Synthesis, 2 <sup>nd</sup> Ed., Wiley & Sons, 1991  5 Harbeson, S.L., et al., "Stereospecific synthesis of peptidyl β-keto amides as inhibitors of calpain," J. Med. Chem., 1994, 37, 2918-2929  6 Lehninger, Biochemistry, 2 <sup>nd</sup> Ed., Worth Publishers, Inc., 1975, 73-75  7 Meyer, S.L., et al., "Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system," Biochem. J., 1996, 314, 511-519  8 Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, Vol. 120(13), page 1236, Abstract No. 164625  9 Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040								
<ul> <li>Not Yet Assigned</li> <li>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</li> <li>1 Amparo, E. C. et al., "Preparation of .alphaaminoboronic acid and ester as inhibitors of thrombin", Chemical Abstract, 1996, Vol. 125(17), page 1172, Abstract No. 222432</li> <li>2 Amparo, E.C. et al., "Boronic acid and ester inhibitors of thrombin", Chemical Abstract, 1997, Vol. 126(3), page 594, Abstract No. 31466</li> <li>3 Bihovsky et al., "Preparation of benzothiazine- and related heterocyclic group-containing amino acids as cysteine and serine protease inhibitors", Chemical Abstract, 1998, Vol. 129, WO 98/21186, Abstract No. 28214</li> <li>* 4 Green, T.W., et al., Protective Groups in Organic Synthesis, 2<sup>nd</sup> Ed., Wiley &amp; Sons, 1991</li> <li>5 Harbeson, S.L., et al., "Stereospecific synthesis of peptidyl β-keto amides as inhibitors of calpain," J. Med. Chem., 1994, 37, 2918-2929</li> <li>6 Lehninger, Biochemistry, 2<sup>nd</sup> Ed., Worth Publishers, Inc., 1975, 73-75</li> <li>7 Meyer, S.L., et al., "Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system," Biochem. J., 1996, 314, 511-519</li> <li>8 Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, Vol. 120(13), page 1236, Abstract No. 164625</li> <li>9 Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040</li> </ul>				_		· ·		
<ol> <li>Amparo, E. C. et al., "Preparation of .alphaaminoboronic acid and ester as inhibitors of thrombin", Chemical Abstract, 1996, Vol. 125(17), page 1172, Abstract No. 222432</li> <li>Amparo, E.C. et al., "Boronic acid and ester inhibitors of thrombin", Chemical Abstract, 1997, Vol. 126(3), page 594, Abstract No. 31466</li> <li>Bihovsky et al., "Preparation of benzothiazine- and related heterocyclic group-containing amino acids as cysteine and serine protease inhibitors", Chemical Abstract, 1998, Vol. 129, WO 98/21186, Abstract No. 28214</li> <li>Green, T.W., et al., Protective Groups in Organic Synthesis, 2<sup>nd</sup> Ed., Wiley &amp; Sons, 1991</li> <li>Harbeson, S.L., et al., "Stereospecific synthesis of peptidyl β-keto amides as inhibitors of calpain," J. Med. Chem., 1994, 37, 2918-2929</li> <li>Lehninger, Biochemistry, 2<sup>nd</sup> Ed., Worth Publishers, Inc., 1975, 73-75</li> <li>Meyer, S.L., et al., "Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system," Biochem. J., 1996, 314, 511-519</li> <li>Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, Vol. 120(13), page 1236, Abstract No. 164625</li> <li>Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040</li> </ol>								
inhibitors of thrombin", Chemical Abstract, 1996, Vol. 125(17), page 1172, Abstract No. 222432  2 Amparo, E.C. et al., "Boronic acid and ester inhibitors of thrombin", Chemical Abstract, 1997, Vol. 126(3), page 594, Abstract No. 31466  3 Bihovsky et al., "Preparation of benzothiazine- and related heterocyclic groupcontaining amino acids as cysteine and serine protease inhibitors", Chemical Abstract, 1998, Vol. 129, WO 98/21186, Abstract No. 28214  * Green, T.W., et al., Protective Groups in Organic Synthesis, 2 <sup>nd</sup> Ed., Wiley & Sons, 1991  5 Harbeson, S.L., et al., "Stereospecific synthesis of peptidyl β-keto amides as inhibitors of calpain," J. Med. Chem., 1994, 37, 2918-2929  6 Lehninger, Biochemistry, 2 <sup>nd</sup> Ed., Worth Publishers, Inc., 1975, 73-75  7 Meyer, S.L., et al., "Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system," Biochem. J., 1996, 314, 511-519  8 Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, Vol. 120(13), page 1236, Abstract No. 164625  9 Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040	O	THE	R DOCUMENTS (Includ	ling Author	, Title, Date,	Pertinent Pages, Etc.)		
<ul> <li>Abstract, 1997, Vol. 126(3), page 594, Abstract No. 31466</li> <li>3 Bihovsky et al., "Preparation of benzothiazine- and related heterocyclic group-containing amino acids as cysteine and serine protease inhibitors", Chemical Abstract, 1998, Vol. 129, WO 98/21186, Abstract No. 28214</li> <li>* Green, T.W., et al., Protective Groups in Organic Synthesis, 2<sup>nd</sup> Ed., Wiley &amp; Sons, 1991</li> <li>5 Harbeson, S.L., et al., "Stereospecific synthesis of peptidyl β-keto amides as inhibitors of calpain," J. Med. Chem., 1994, 37, 2918-2929</li> <li>6 Lehninger, Biochemistry, 2<sup>nd</sup> Ed., Worth Publishers, Inc., 1975, 73-75</li> <li>7 Meyer, S.L., et al., "Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system," Biochem. J., 1996, 314, 511-519</li> <li>8 Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, Vol. 120(13), page 1236, Abstract No. 164625</li> <li>9 Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040</li> </ul>		1	inhibitors of thrombin", Chemical Abstract, 1996, Vol. 125(17), page 1172, Abstract					
<ul> <li>containing amino acids as cysteine and serine protease inhibitors", Chemical Abstract, 1998, Vol. 129, WO 98/21186, Abstract No. 28214</li> <li>* Green, T.W., et al., Protective Groups in Organic Synthesis, 2<sup>nd</sup> Ed., Wiley &amp; Sons, 1991</li> <li>5 Harbeson, S.L., et al., "Stereospecific synthesis of peptidyl β-keto amides as inhibitors of calpain," J. Med. Chem., 1994, 37, 2918-2929</li> <li>6 Lehninger, Biochemistry, 2<sup>nd</sup> Ed., Worth Publishers, Inc., 1975, 73-75</li> <li>7 Meyer, S.L., et al., "Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system," Biochem. J., 1996, 314, 511-519</li> <li>8 Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, Vol. 120(13), page 1236, Abstract No. 164625</li> <li>9 Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040</li> </ul>		2						
<ul> <li>Harbeson, S.L., et al., "Stereospecific synthesis of peptidyl β-keto amides as inhibitors of calpain," J. Med. Chem., 1994, 37, 2918-2929</li> <li>Lehninger, Biochemistry, 2<sup>nd</sup> Ed., Worth Publishers, Inc., 1975, 73-75</li> <li>Meyer, S.L., et al., "Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system," Biochem. J., 1996, 314, 511-519</li> <li>Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, Vol. 120(13), page 1236, Abstract No. 164625</li> <li>Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040</li> </ul>		3	containing amino acids as cysteine and serine protease inhibitors", Chemical					
<ul> <li>inhibitors of calpain," J. Med. Chem., 1994, 37, 2918-2929</li> <li>6 Lehninger, Biochemistry, 2<sup>nd</sup> Ed., Worth Publishers, Inc., 1975, 73-75</li> <li>7 Meyer, S.L., et al., "Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system," Biochem. J., 1996, 314, 511-519</li> <li>8 Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, Vol. 120(13), page 1236, Abstract No. 164625</li> <li>9 Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040</li> </ul>	*	4						
<ul> <li>7 Meyer, S.L., et al., "Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system," <i>Biochem. J.</i>, 1996, 314, 511-519</li> <li>8 Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, <i>Vol. 120(13)</i>, page 1236, Abstract No. 164625</li> <li>9 Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, <i>Vol. 116(25)</i>, page 838, Abstract No. 256040</li> </ul>					= = : :			
human calpain I produced using the baculovirus expression system," <i>Biochem. J.</i> , 1996, 314, 511-519  8 Nagase, H. et al., "Preparation of morphinan derivatives as analgesics and diuretics", Chemical Abstract, 1994, Vol. 120(13), page 1236, Abstract No. 164625  9 Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040		6	Lehninger, Biochemistry	y, 2 <sup>nd</sup> Ed., Worth Publishers, Inc., <b>1975</b> , 73-75				
Chemical Abstract, <b>1994</b> , <i>Vol. 120(13)</i> , page 1236, Abstract No. 164625 <b>9</b> Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, <b>1992</b> , <i>Vol. 116(25)</i> , page 838, Abstract No. 256040		human calpain I produced using the baculovirus expression system," Biochem. J.,						
antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040		8						
* 10 Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 1980		9	9 Tsushima, T. et al., "Preparation of amino acid derivatives as digestive tract hormone antagonists", Chemical Abstract, 1992, Vol. 116(25), page 838, Abstract No. 256040					
	*	10 Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 1980						
EXAMINER DATE CONSIDERED	EXAMINER	1			DATE CON	SIDERED		

<sup>\*</sup> A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.





Form PTC	0-1449 Modified	Docket No. CEPH-2313/CP188-C	Application No. 10/685,923				
Cited	nt and Publications by Applicant sheets if necessary)	Applicant Sankar Chatterjee, et al.					
	ment of Commerce Trademark Office	Filing Date October 14, 2003	Group Not Yet Assigned				
		Confirmation No. Not Yet Assigned					
ОТНЕ	R DOCUMENTS (Inclu	iding Author, Title, Date,	Pertinent Pages, Etc.)				
11		Winterbottom, et al., "Studies in chemotherapy, XV. Amides of pantoyltaurine," J. Am. Chem. Soc., 1947, 69, 1393-1401					
12	Bihovsky, R., et al., US	Spatful, <b>1999</b> , 110318					
13	Bihovsky, R., et al., Ca	olus, <b>1998</b> , 129, 28214					
14	Chatterjee, S., et al., Co	aplus, <b>1999</b> , 131, 337341					
15	Chatterjee, S., et al., Co	aplus, <b>1999</b> , 131, 306757					
EXAMINER		DATE CON	SIDERED				





	28	WO 96/14857	05/1996	PCT			
•	27	WO 95/00535	01/1995	PCT			
	26	0 604 183 A1	06/29/94	EP			
Examiner Initial		Document No.	Date	Country		Tra YES	nslation NO
		FOR	EIGN PATI	ENT DOCUMENTS	·		
	25	5,650,508	07/1997	Powers		544	168
	24	5,646,121	07/1997	Häbich, et al.		514	18
	23	5,614,649	03/1997	Iqbal, et al.		554	56
	22	5,610,297	03/1997	Powers		544	168
	21	5,563,127	10/1996	Amparo, et al.		514	64
	20	5,514,694	05/1996	Powers, et al.		514	357
	19	5,444,042	08/1995	Bartus, et al.		514	2
	18	5,340,825	08/1994	Horwell, et al.		514	339
	17	5,162,500	11/1992	Takeuchi, et al.		530	330
	16	5,034,376	07/1991	Hoover, et al.		514	18
Examiner Initial		Document No.	Date	Name		Class	Subclass
TO .	1	<del></del>	S. PATENT	T DOCUMENTS		T.	
U.S. Department of Commerce Patent and Trademark Office				Filing Date October 14, 2003	Group Not Yet Assigned		
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Applicant Sankar Chatterjee, et al.			
Form PTO-1449 Modified				Docket No. CEPH- 2313/CP188-C	Application No. 10/685,923		





Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Docket No. CEPH- 2313/CP188-C  Application No. 10/685,923			
				Applicant Sankar Chatterjee, et al.			
	U.S. Department of Commerce Patent and Trademark Office				Filing Date Group October 14, 2003 Not Yet Assigned		
		U.	S. PATEN	T DOCUMENTS			
Examiner Initial		Document No.	Date	Name		Class	Subclass
	31	5,658,885	08/1997	Lee, et al.		514	19
	32	5,698,538	12/1997	Amparo, et al.		514	64
	33	5,763,576	06/1998	Powers		530	330
	34	5,952,328	09/1999	Bihovsky, et al.		514	223.2
	35	6,083,944	07/2000	Chatterjee, et al.		514	235.2
	36	6,310,057	10/2001	Chatterjee, et al.		514	212.08
	37	6,150,378	11/21/00	Chatterjee, et al.		514	336
	38	6,288,231 B1	09/11/01	Chatterjee, et al.		544	316
		EOD	ELCAL DATE	ENT DOCUMENTS			
Examiner	1	FOR	LIGN FATI	DOCUMENTS		Tra	nslation
Initial		Document No.	Date	Country		YES	NO
	39	WO 98/25883	06/1998	PCT			
	40	WO 96/16070	05/1998	PCT			
EXAMINER	R.			DATE CONSIDER	RED		